Kiniksa Pharmaceuticals Ltd expected to post a loss of 42  cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

18/02/2022 14:29

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 21 (estimated). 
    * The Hamilton Bermuda-based   company is expected to report
revenue of $20.724 million, according to the mean estimate from
4 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Kiniksa
Pharmaceuticals
Ltd is for a loss of 42 cents per share. For the same quarter
last year, the company reported a loss of 79 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $28​, about 60.9% above​ its last closing
price of $10.94. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.65       -0.65      -0.44     Beat    32
 Jun. 30 2021  -0.94       -0.79      -0.61     Beat    23
 Mar. 31 2021  -0.63       -0.72      -0.72     Met     0.7​
 Dec. 31 2020  -0.61       -0.62      -0.79     Missed  -26.9
 ​​Sep.        -0.60       -0.60      -0.66     Missed  -9.1
 30 2020                                                
 Jun. 30 2020  -0.60       -0.63      -0.65     Missed  -3.8​
 Mar. 31 2020  -0.67       -0.63      -0.48     Beat    24.3
 Dec. 31 2019  -0.64       -0.62      -0.58     Beat    6.5
 This summary was machine generated February 18 at 14:29 GMT. 
All figures in US dollars  unless otherwise stated